Rise Therapeutics, LLC

Rise Therapeutics, LLC is a US-based biotechnology company focused on advancing innovative oral immunotherapeutics to target immune dysfunction across various diseases including autoimmune disorders and cancer. Rise Therapeutics specializes in developing first-in-class oral immunotherapeutics, with headquarters in Rockville, US. Founded by Neil Fanger, the company recently raised USD 200,000 from Maryland Technology Development Corporation in May 2023, marking its fifth funding deal. Rise Therapeutics specializes in the development of first-in-class oral immunotherapeutics, primarily focusing on its proprietary Oral BioModulators.

These innovative products leverage advanced synthetic biology-based approaches and target specific immune pathways to effectively address underlying immune dysfunctions that contribute to various diseases, including autoimmune disorders and cancer. The company’s flagship candidates, such as R-3750 and R-5780, are undergoing clinical trials aimed at treating conditions like ulcerative colitis and various cancers. The Oral BioModulators are designed for oral administration, enhancing patient compliance compared to traditional therapies. Rise Therapeutics markets its products in the United States and plans to expand its reach internationally as clinical validation progresses, targeting healthcare providers, research institutions, and specialty pharmacies to ensure a broad distribution network.

Rise Therapeutics generates revenue through partnerships with healthcare organizations, academic institutions, and pharmaceutical companies, focusing on collaborative development and clinical testing of its oral immunotherapeutics. The company engages in direct collaborations with clinical research organizations (CROs) for trial management, which establishes a structured transaction framework that includes funding for clinical trials and shared milestones. Revenue is expected to accrue from successful trial outcomes leading to commercial licensing agreements or product sales once the therapies receive regulatory approvals. The pricing structure for the products will be determined upon successful market entry, reflecting the value brought by its unique therapeutic approach.

Products like R-3750 and R-5780 will serve as the cornerstone of Rise Therapeutics’ revenue model as they advance through the clinical stages and into commercialization. In May 2023, Rise Therapeutics, LLC raised USD 200,000 in venture funding from returning investor Maryland Technology Development Corporation. The company will use the funding to support the ongoing clinical development of its drug candidates. As clinical validation progresses, Rise Therapeutics plans to expand its market reach internationally, targeting healthcare providers and research institutions beyond the United States.